The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.

Thrombomodulin (TM) is an endothelial anticoagulant cofactor that promotes thrombin-mediated formation of activated protein C (APC). We have found that the N-terminal lectin-like domain (D1) of TM has unique antiinflammatory properties. TM, via D1, binds high-mobility group-B1 DNA-binding protein (HMGB1), a factor closely associated with necrotic cell damage following its release from the nucleus, thereby preventing in vitro leukocyte activation, in vivo UV irradiation-induced cutaneous inflammation, and in vivo lipopolysaccharide-induced lethality. Our data also demonstrate antiinflammatory properties of a peptide spanning D1 of TM and suggest its therapeutic potential. These findings highlight a novel mechanism, i.e., sequestration of mediators, through which an endothelial cofactor, TM, suppresses inflammation quite distinctly from its anticoagulant cofactor activity, thereby preventing the interaction of these mediators with cell surface receptors on effector cells in the vasculature.

[1]  E. Schleicher,et al.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.

[2]  T. Nakajima,et al.  Antibiotic cyclic AMP signaling by “primed” leukocytes confers anti‐inflammatory cytoprotection , 2003, Journal of leukocyte biology.

[3]  S. Yamada,et al.  High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. , 2003, Clinical chemistry.

[4]  Xiaodan Wang,et al.  S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. , 2003, Diabetes.

[5]  P. Ward,et al.  The enigma of sepsis. , 2003, The Journal of clinical investigation.

[6]  U. Andersson,et al.  High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. , 2003, Arthritis and rheumatism.

[7]  Michael Bustin,et al.  Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. , 2003, Blood.

[8]  M. Yamakuchi,et al.  High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. , 2003, Arthritis and rheumatism.

[9]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[10]  P. Hellings,et al.  The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways , 2002, The Journal of experimental medicine.

[11]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[12]  W. Ruf,et al.  Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway , 2002, Science.

[13]  Y. Yuzawa,et al.  Effects of human soluble thrombomodulin on experimental glomerulonephritis. , 2002, Kidney international.

[14]  T. van der Poll,et al.  Regulatory role of cytokines in disseminated intravascular coagulation. , 2001, Seminars in thrombosis and hemostasis.

[15]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[16]  Jeffrey I. Weitz,et al.  Characterization of a Mouse Model for Thrombomodulin Deficiency , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[17]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[18]  K. Tracey,et al.  High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes , 2000, The Journal of experimental medicine.

[19]  M. Dake,et al.  Thrombomodulin overexpression to limit neointima formation. , 2000, Circulation.

[20]  J. Jester,et al.  A role for NF-κB–dependent gene transactivation in sunburn , 2000 .

[21]  S. Arii,et al.  Pretreatment with Soluble Thrombomodulin Prevents Intrasinusoidal Coagulation and Liver Dysfunction following Extensive Hepatectomy in Cirrhotic Rats , 1999, Thrombosis and Haemostasis.

[22]  T. Nakajima,et al.  Inhibition of Thrombin-induced Neuronal Cell Death by Recombinant Thrombomodulin and E5510, a Synthetic Thrombin Receptor Signaling Inhibitor , 1999, Thrombosis and Haemostasis.

[23]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[24]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[25]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[26]  K. Takatsuki,et al.  Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. , 1997, The American journal of physiology.

[27]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[28]  T. Nakajima,et al.  Nonionic contrast agents produce thrombotic effect by inducing adhesion of leukocytes on human endothelium. , 1995, Biochemical and biophysical research communications.

[29]  Hendrik G. Stunnenberg,et al.  Affinity purification of histidine-tagged proteins , 1993, Molecular Biology Reports.

[30]  B. Dahlbäck.  Protein S and C4b-Binding Protein: Components Involved in the Regulation of the Protein C Anticoagulant System , 1991, Thrombosis and Haemostasis.

[31]  S. Yamamoto,et al.  The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. , 1989, The Journal of biological chemistry.

[32]  S. Yamamoto,et al.  A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. , 1989, The Journal of biological chemistry.

[33]  H. Aspöck,et al.  Purification of egg yolk immunoglobulins. A two-step procedure using hydrophobic interaction chromatography and gel filtration. , 1988, Journal of immunological methods.

[34]  S. Yamamoto,et al.  Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. , 1987, The EMBO journal.

[35]  A. Fusco,et al.  Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v‐ras and v‐mos oncogenes and by cotransfection with c‐myc and polyoma middle T genes. , 1987, The EMBO journal.

[36]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[37]  P. Majerus,et al.  Coagulation factor Va binds to human umbilical vein endothelial cells and accelerates protein C activation. , 1984, The Journal of clinical investigation.

[38]  C. Esmon,et al.  Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. , 1982, The Journal of biological chemistry.

[39]  C. Esmon,et al.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Sugimura,et al.  Human FcεRIα–Specific Human Single-Chain Fv (scFv) Antibody with Antagonistic Activity toward IgE/FcεRIα-Binding , 2003 .

[41]  T. Raffin,et al.  The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. , 1996, American journal of respiratory and critical care medicine.

[42]  T. Kislinger,et al.  Blockade of RAGE ± amphoterin signalling suppresses tumour growth and metastases , 2022 .